Mono Pharmacare confirms SDD compliance for FY26
Mono Pharmacare Limited filed its SDD compliance certificate for FY26, confirming the capture of 7 UPSI events with zero non-compliance. The company maintained a secure, non-tamperable database as per SEBI PIT Regulations.
*this image is generated using AI for illustrative purposes only.
Mono Pharmacare Limited has confirmed full compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, regarding the maintenance of a Structured Digital Database (SDD) for the financial year ended March 31, 2026. The certification, filed on May 30, 2026, verifies that the pharmaceutical company successfully captured all required Unpublished Price Sensitive Information (UPSI) events during the period, ensuring robust internal controls and data integrity.
The compliance certificate, issued by Mrs. Ankita Surana of Surana And Kothari Associates LLP, attests that mono pharmacare maintained a secure, non-tamperable system with restricted access. The database is designed to preserve records for eight years and includes a comprehensive audit trail to monitor access and modifications. This infrastructure is critical for preventing insider trading and ensuring transparency in information dissemination.
During the period from April 1, 2025, to March 31, 2026, the company was required to capture seven specific events within the SDD. The certification confirms that all seven events were successfully recorded, with no instances of non-compliance identified. The system captured the nature of the UPSI along with precise date and time stamps, fulfilling the regulatory mandates set forth under Regulation 3(5) and 3(6) of the PIT Regulations.
Key Compliance Metrics for FY26
| Metric | Status |
|---|---|
| UPSI Events Required | 7 |
| UPSI Events Captured | 7 |
| Non-Compliances Reported | Nil |
| Record Retention Period | 8 years |
| Database Security | Non-tamperable with access controls |
The filing was submitted to the National Stock Exchange of India Limited by Panilam Lakhatariya, Managing Director of Mono Pharmacare Limited. The statutory confirmation provided by the practising company secretary underscores the company's adherence to governance standards and its commitment to maintaining a fair and transparent securities market environment.
Historical Stock Returns for Mono Pharmacare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.00% | -6.94% | -9.52% | -42.71% | -57.54% | -62.56% |
How will the implementation of this robust internal control framework influence investor confidence and shareholder value moving forward?
What specific types of strategic UPSI events constituted the seven recorded instances, and what do they suggest about the company's operational activity?
Could this enhanced compliance infrastructure serve as a competitive advantage when attracting foreign institutional investment?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
